EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring a Circulating miRNA Signature for PMM2 ‐ CDG : Initial Insights Toward Diagnosis, Stratification, and Monitoring

Florencia Epifani, Lluc Cabus iD, Gregorio A Nolasco, Mercè Bolasell, Jennifer Pérez, Adrián Alcalá, Patricia Fernández, Esther Lizano iD, Gisela Márquez, Sonia Belmonte, Sílvia Carbonell-Sala, Julien Lagarde und 3 weitere

Journal of Inherited Metabolic Disease · 2025-11 · 48 (6)

DOI: 10.1002/jimd.70104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 13.10.2025. Verfasst von Florencia Epifani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology Department, Hospital Sant Joan de Déu, Barcelona, Spain. Hauptthemen laut MEDLINE: Congenital Disorders of Glycosylation, Phosphotransferases (Phosphomutases), Circulating MicroRNA, MicroRNAs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHGRI NIH HHS, Spanish Ministry of Science and Innovation, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphomannomutase deficiency (PMM2‐CDG) is the most common congenital disorder of glycosylation, characterized by variable early‐onset neurological (hypotonia, cerebellar syndrome, developmental delay) and multi‐organ manifestations. Although several clinical trials are ongoing, current biomarkers lack prognostic or monitoring utility. Emerging transcriptomic studies suggest dysregulated pathways in PMM2‐CDG, but miRNAs, key gene expression regulators, remain unexplored. This cross‐sectional study aims to investigate a circulating miRNA signature that may distinguish PMM2‐CDG patients from unaffected controls, providing an initial framework for future studies on potential predictive and monitoring tools. Differential gene expression analysis was used to identify significant differentially expressed (DE) miRNAs, while machine learning models (LASSO, XGBoost) were applied to create an miRNA predictive signature. Dysregulated miRNA pathways analysis provided insights into affected tissues and cellular mechanisms. An optimized protocol addressing challenges in pediatric blood samples was implemented. miRNA profiles from blood samples of 28 PMM2‐CDG patients and 67 unaffected controls were analyzed, identifying six DE miRNAs. Regarding machine learning models, XGBoost achieved the best performance (AUC 0.917). Biological analysis revealed that DE miRNAs influence neurological, endocrinological, immunological, and cellular pathways related to the PMM2‐CDG phenotype. Notably, miR‐122‐5p emerged as a highly predictive marker, indicating liver and neurological involvement. Circulating miRNAs represent a promising, minimally invasive avenue for further investigation. While preliminary evidence of their potential diagnostic utility is provided, additional validation in larger and more diverse populations is required to determine their relevance for clinical stratification or monitoring in PMM2‐CDG, contributing to future biomarker‐driven personalized medicine efforts in this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Congenital Disorders of GlycosylationPhosphotransferases (Phosphomutases)Circulating MicroRNAMicroRNAsHumansMaleFemaleBiomarkersChild, PreschoolCross-Sectional StudiesChildMachine LearningInfantGene Expression ProfilingCase-Control StudiesAdolescent

Stichwörter der Autor:innen

PMM2‐CDGbiomarkersmachine learningmiRNApathway dysregulationtranscriptomic

Substanzen

Phosphotransferases (Phosphomutases)BiomarkersCirculating MicroRNAMicroRNAsphosphomannomutase 2, human

Autor:innen und Institutionen

  • Pediatric Neurology Department, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
  • Flomics Biotech, Barcelona, Spain.
  • Genetic and Molecular Medicine Department, Pediatric Institute for Rare Diseases, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Institut Català de Paleontologia Miquel Crusafont (ICP-CERCA), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Unidad de Paleobiología, ICP-CERCA, Unidad Asociada al CSIC Por el IBE UPF-CSIC, Barcelona, Spain.

ORCID-Profile: Lluc Cabus, Esther Lizano, Mercedes Serrano

Förderung

  • NHGRI NIH HHS
  • Spanish Ministry of Science and Innovation
  • Generalitat de Catalunya
  • Instituto de Salud Carlos III
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • National Human Genome Research Institute

Zitieren

APA

Epifani, F., Cabus, L., Nolasco, G. A., Bolasell, M., Pérez, J., Alcalá, A., Fernández, P., Lizano, E., Márquez, G., Belmonte, S., Carbonell-Sala, S., Lagarde, J., Curado, J., Hernando-Davalillo, C., & Serrano, M. (2025). Exploring a Circulating miRNA Signature for PMM2 ‐ CDG : Initial Insights Toward Diagnosis, Stratification, and Monitoring. Journal of Inherited Metabolic Disease, 48(6). https://doi.org/10.1002/jimd.70104

Vancouver

Epifani F, Cabus L, Nolasco GA, Bolasell M, Pérez J, Alcalá A, et al. Exploring a Circulating miRNA Signature for PMM2 ‐ CDG : Initial Insights Toward Diagnosis, Stratification, and Monitoring. Journal of Inherited Metabolic Disease. 2025;48(6). doi:10.1002/jimd.70104

BibTeX
@article{Epifani2025,
  author = {Epifani, Florencia and Cabus, Lluc and Nolasco, Gregorio A and Bolasell, Mercè and Pérez, Jennifer and Alcalá, Adrián and Fernández, Patricia and Lizano, Esther and Márquez, Gisela and Belmonte, Sonia and Carbonell-Sala, Sílvia and Lagarde, Julien and Curado, Joao and Hernando-Davalillo, Cristina and Serrano, Mercedes},
  title = {Exploring a Circulating miRNA Signature for PMM2 ‐ CDG : Initial Insights Toward Diagnosis, Stratification, and Monitoring},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {6},
  doi = {10.1002/jimd.70104}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche